JP2013511526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511526A5 JP2013511526A5 JP2012539987A JP2012539987A JP2013511526A5 JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5 JP 2012539987 A JP2012539987 A JP 2012539987A JP 2012539987 A JP2012539987 A JP 2012539987A JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- agent
- substituted
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26234209P | 2009-11-18 | 2009-11-18 | |
| US61/262,342 | 2009-11-18 | ||
| US29203210P | 2010-01-04 | 2010-01-04 | |
| US61/292,032 | 2010-01-04 | ||
| PCT/US2010/056942 WO2011062939A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511526A JP2013511526A (ja) | 2013-04-04 |
| JP2013511526A5 true JP2013511526A5 (https=) | 2015-06-11 |
Family
ID=43384585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539987A Ceased JP2013511526A (ja) | 2009-11-18 | 2010-11-17 | 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20120232087A1 (https=) |
| EP (1) | EP2501370A1 (https=) |
| JP (1) | JP2013511526A (https=) |
| KR (1) | KR20120107962A (https=) |
| CN (2) | CN102665700A (https=) |
| AU (1) | AU2010322114B2 (https=) |
| BR (1) | BR112012011823A2 (https=) |
| CA (1) | CA2781210A1 (https=) |
| CL (1) | CL2012001271A1 (https=) |
| IL (1) | IL219636A0 (https=) |
| MA (1) | MA33739B1 (https=) |
| MX (1) | MX2012005695A (https=) |
| NZ (1) | NZ599964A (https=) |
| PH (1) | PH12012500911A1 (https=) |
| RU (1) | RU2012125152A (https=) |
| TN (1) | TN2012000205A1 (https=) |
| WO (1) | WO2011062939A1 (https=) |
| ZA (1) | ZA201203325B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627911T3 (es) | 2009-11-18 | 2017-08-01 | Plexxikon, Inc. | Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer |
| SG194800A1 (en) * | 2011-06-02 | 2013-12-30 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| EP2914253B1 (en) | 2012-11-05 | 2018-01-03 | NantBioScience, Inc. | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway |
| CN103524535B (zh) * | 2013-10-16 | 2016-07-13 | 苏州云轩医药科技有限公司 | 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物 |
| EP3565520B1 (en) | 2017-01-06 | 2026-02-25 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
| DK3786160T3 (da) | 2017-10-27 | 2022-08-22 | Boehringer Ingelheim Int | Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer |
| US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| US20210346385A1 (en) * | 2018-09-21 | 2021-11-11 | MSB Holdings, Inc | Taste-masked dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| JP5161102B2 (ja) | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| CA2681162C (en) * | 2007-03-15 | 2015-11-24 | Novartis Ag | Benzyl and pyridine derivatives as modulators of hedgehog pathway |
| BR122021010386B1 (pt) * | 2007-06-07 | 2021-08-03 | Sun Pharma Global Fze | Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog |
| US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009112266A1 (en) * | 2008-03-12 | 2009-09-17 | Ludwig-Maximilians-Universität | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| UA102250C2 (ru) * | 2008-04-29 | 2013-06-25 | Эли Лилли Энд Компани | Двухзамещенные фталазины - антагонисты проводящего пути hedgehog |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
-
2010
- 2010-11-17 KR KR1020127015545A patent/KR20120107962A/ko not_active Withdrawn
- 2010-11-17 JP JP2012539987A patent/JP2013511526A/ja not_active Ceased
- 2010-11-17 EP EP10782767A patent/EP2501370A1/en not_active Withdrawn
- 2010-11-17 MX MX2012005695A patent/MX2012005695A/es not_active Application Discontinuation
- 2010-11-17 BR BR112012011823A patent/BR112012011823A2/pt not_active IP Right Cessation
- 2010-11-17 WO PCT/US2010/056942 patent/WO2011062939A1/en not_active Ceased
- 2010-11-17 CN CN2010800517592A patent/CN102665700A/zh active Pending
- 2010-11-17 RU RU2012125152/15A patent/RU2012125152A/ru unknown
- 2010-11-17 US US13/509,857 patent/US20120232087A1/en not_active Abandoned
- 2010-11-17 PH PH1/2012/500911A patent/PH12012500911A1/en unknown
- 2010-11-17 CA CA2781210A patent/CA2781210A1/en not_active Abandoned
- 2010-11-17 CN CN201410410334.6A patent/CN104224791A/zh active Pending
- 2010-11-17 NZ NZ599964A patent/NZ599964A/en not_active IP Right Cessation
- 2010-11-17 AU AU2010322114A patent/AU2010322114B2/en not_active Ceased
-
2012
- 2012-05-07 ZA ZA2012/03325A patent/ZA201203325B/en unknown
- 2012-05-07 TN TNP2012000205A patent/TN2012000205A1/en unknown
- 2012-05-07 IL IL219636A patent/IL219636A0/en unknown
- 2012-05-11 MA MA34856A patent/MA33739B1/fr unknown
- 2012-05-16 CL CL2012001271A patent/CL2012001271A1/es unknown
-
2014
- 2014-10-09 US US14/510,713 patent/US20150025074A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511526A5 (https=) | ||
| ES2609767T3 (es) | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK | |
| Nonnenmacher et al. | RIST: A potent new combination therapy for glioblastoma | |
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| JP6648040B2 (ja) | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| ES2861180T3 (es) | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etan-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer | |
| JP7278776B2 (ja) | 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ | |
| JP2017521499A (ja) | 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療 | |
| JP2022145800A (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| JP2018510869A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ | |
| Mazzoletti et al. | PI3K/AKT/mTOR inhibitors in ovarian cancer | |
| AU2013341271A1 (en) | Combination therapy | |
| JP5440985B2 (ja) | メラノーマの治療 | |
| JP2013511526A (ja) | 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物 | |
| CA3253034A1 (en) | METHODS FOR TREATMENT OF MYELOID MALIGNITIS USING A BCL-2 INHIBITOR | |
| ES2685974T3 (es) | Derivados de cefalosporina para tratar el cáncer | |
| ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
| MX2023011814A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer. | |
| Kasper et al. | Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? | |
| RU2012123970A (ru) | Тивозаниб и темсиролимус в комбинации | |
| CN102105148B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
| RU2009128186A (ru) | Производные трициклических аминов в качестве ингибиторов тирозинкиназы |